Fibrate treatment for primary biliary cirrhosis

Current Opinion in Gastroenterology

Volumn 30, Issue 3, 2014, Pages 279-286

  Cuperus, Frans J C ^a   Halilbasic, Emina ^a   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

fibrate; multidrug resistance protein 3; peroxisome proliferator activated receptor; primary biliary cirrhosis; ursodeoxycholic acid

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BEZAFIBRATE; BILIRUBIN; BUDESONIDE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; URSODEOXYCHOLIC ACID; ANTILIPEMIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTICHOLESTATIC EFFECT; ANTIFIBROTIC EFFECT; ANTIINFLAMMATORY ACTIVITY; BILIRUBIN BLOOD LEVEL; CHEMICAL ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; FIRST PASS EFFECT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER; META ANALYSIS (TOPIC); MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; DRUG COMBINATION; LIVER CIRRHOSIS, BILIARY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; FIBRIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER CIRRHOSIS, BILIARY; TREATMENT FAILURE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84898546994     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000056     Document Type: Review

References (98)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353:1261-1273.
2. Prince MI, James OFW the epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003; 7:795-819.
3. Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 2007; 41:494-500.
4. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52:745-758.
5. Baldursdottir TR, Bergmann OM, Jonasson JG, et al the epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol 2012; 24:824-830.
6. Metcalf JV, Bhopal RS, Gray J, et al. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997; 26:830-836.
7. James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 1999; 30:390-394.
8. Rautiainen H, Salomaa V, Niemela° S, et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol 2007; 42:1347-1353.
9. Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int 2014; doi: 10.1111/liv.12434. [Epub ahead of print]
10. Jones DE, Watt FE, Metcalf JV, et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999; 30:402-407.
11. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004; 127:485-492.
12. Xu L, Shen Z, Guo L, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci USA 2003; 100:8454-8459.
13. Leung PSC, Quan C, Park O, et al. Immunization with a xenobiotic 6-bromo-hexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 2003; 170:5326-5332.
14. Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006; 43:525-531.
15. Gershwin ME, Mackay IR the causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008; 47:737-745.
16. Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial auto-antibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001; 34:243-248.
17. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatol-ogy 2009; 50:291-308.
18. Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348:1399-1402.
19. Springer J, Cauch-Dudek K, O'Rourke K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94:47-53.
20. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51:237-267.
21. Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999; 30:830-835.
22. Corpechot C, Carrat F, Bahr A, et al the effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128:297-303.
23. Liermann Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33:22-27.
24. Lee J, Belanger A, Doucette JT, et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5:1313-1315.
25. Kuiper EMM, Hansen BE, Metselaar HJ, et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol 2010; 10:144.
26. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to urso-deoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepa-tology 2008; 48:871-877.
27. Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12:; CD000551.
28. Poupon R-E, Lindor KD, Parés A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39:12-16.
29. Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29:1007-1012.
30. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72:1137-1140.
31. Huet P-M, Vincent C, Deslaurier J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterol-ogy 2008; 135:1552-1560.
32. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.
33. Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101:1529-1538.
34. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl 1):S3-S12.
35. Parés A, Caballeŕia L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130:715-720.
36. Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55:1361-1367.
37. Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxy-cholic acid. Gastroenterology 2009; 136:1281-1287.
38. Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105:2186-2194.
39. Azemoto N, Abe M, Murata Y, et al. Early biochemical response to ursodeoxy-cholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol 2009; 44:630-634.
40. Azemoto N, Kumagi T, Abe M, et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011; 41:310-317.
41. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144:560-569; e7-quiz e13-4.
42. Kaplan MM, Poupon R. Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol. Hepatology 2009; 50:652-1652.
43. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxy-cholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117:918-925.
44. Rautiainen H, Kärkkäinen P, Karvonen A-L, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41:747-752.
45. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to urso-deoxycholic acid. Hepatology 2000; 31:318-323.
46. Hempfling W, Grünhage F, Dilger K, et al. Pharmacokinetics and pharma-codynamic action of budesonide in early-and late-stage primary biliary cirrhosis. Hepatology 2003; 38:196-202.
47. Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis 2013; 17:161-189.
48. Mason A, Luketic V, Lindor K, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology 2010; 52:; 357A.
49. Hirschfield G, Mason A, Gordon S, et al. A long term safety extension trial of the farnesoid X receptor (FXR) agonist obeticholic acid and UDCA in primary biliary cirrosis (PBC). Hepatology 2011; 54:; 429A.
50. Kowdley KV, Jones D, Luketic V, et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J of Hepatol 2011; 54:S13.
51. Mason AL, Farr GH, Xu L, et al. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastro-enterol 2004; 99:2348-2355.
52. Mason AL, Lindor KD, Bacon BR, et al. Clinical trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; 28:886-894.
53. Tsuda M, Moritoki Y, Lian Z-X, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012; 55:512-521.
54. Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastro-enterol 2013; 108:933-941.
55. Day AP, Feher MD, Chopra R, et al the effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metab Clin Exp 1993; 42:839-842.
56. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 1996; 137:354-366.
57. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005; 51:85-94.
58. Bookout AL, Jeong Y, Downes M, et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006; 126:789-799.
59. Matsumoto T, Miyazaki H, Nakahashi Y, et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004; 30:125-136.
60. Shoda J, Inada Y, Tsuji A, et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. J Lipid Res 2004; 45:1813-1825.
61. Kok T, Bloks VW, Wolters H, et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003; 369:539-547.
62. Ghonem NS, Ananthanarayanan M, Soroka CJ, et al. PPARa activates human MDR3/ABCB4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology 2014; 59:1030-1042.
63. Trauner M, Fickert P, Halilbasic E, et al. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr 2008; 158:542-548.
64. Enjoji M, Yada R, Fujino T, et al the state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol Int 2009; 3:490-496.
65. Nakamuta M, Fujino T, Yada R, et al therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther 2010; 48:22-28.
66. Marrapodi M, Chiang JY. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Lipid Res 2000; 41:514-520.
67. Post SM, Duez H, Gervois PP, et al. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arter-ioscler Thromb Vasc Biol 2001; 21:1840-1845.
68. Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013; 57:1931-1941.
69. Ghonem NS, Boyer JL. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology 2013; 57:1691-1693.
70. Delerive P, Gervois P, Fruchart JC, et al. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000; 275: 36703-36707.
71. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275: 35715-35722.
72. Marra F, DeFranco R, Robino G, et al. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol 2005; 11:4931-4938.
73. Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014; 34:197-203.
74. Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis 2012; 13:219-224.
75. Takeuchi Y, Ikeda F, Fujioka S-I, et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol 2011; 26:1395-1401.
76. Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011; 33:235-242.
77. Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010; 44:371-373.
78. Liberopoulos EN, Florentin M, Elisaf MS, et al. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010; 4:120-126.
79. Walker LJ, Newton J, Jones DEJ, et al. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009; 49:337-338; author reply 338.
80. Iwasaki S, Ohira H, Nishiguchi S, et al the efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatology Research 2008; 38:557-564.
81. Kita R, Takamatsu S, Kimura T, et al. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006; 41:686-692.
82. Ohmoto K, Yoshioka N, Yamamoto S. Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol 2006; 41:502-503.
83. Nakamuta M, Enjoji M, Kotoh K, et al. Long-term fibrate treatment for PBC. J Gastroenterol 2005; 40:546-547.
84. Akbar SMF, Furukawa S, Nakanishi S, et al therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol 2005; 40:157-163.
85. Itakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004; 29:216-222.
86. Dohmen K, Mizuta T, Nakamuta M, et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10: 894-898.
87. Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38:573-578.
88. Ohira H, Sato Y, Ueno T, et al. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97:2147-2149.
89. Yano K, Kato H, Morita S, et al. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002; 97:1075-1077.
90. Kurihara T, Maeda A, Shigemoto M, et al. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 2002; 97:212-214.
91. Ohmoto K, Mitsui Y, Yamamoto S. Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver 2001; 21:223-224.
92. Kurihara T, Niimi A, Maeda A, et al. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000; 95:2990-2992.
93. Nakai S, Masaki T, Kurokohchi K, et al. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95:326-327.
94. Miyaguchi S, Ebinuma H, Imaeda H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 2000; 47:1518-1521.
95. Iwasaki S, Tsuda K, Ueta H, et al. Bezafibrate may have a beneficial effect in precirrhotic primary biliary cirrhosis. Hepatol Res 1999; 16:12-18.
96. Iwasaki S, Akisawa N, Saibara T, et al. Fibrate for treatment of primary biliary cirrhosis. Hepatol Res 2007; 37 (Suppl 3):S515-S517.
97. Summerfield JA, Elias E, Sherlock S. Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones. Gastroenterology 1975; 69:998-1000.
98. Schaffner F. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1969; 57:253-255.